請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/83518完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 李財坤(Tsai-Kun Li) | |
| dc.contributor.author | Yu-Lin Lai | en |
| dc.contributor.author | 賴宥菱 | zh_TW |
| dc.date.accessioned | 2023-03-19T21:09:26Z | - |
| dc.date.copyright | 2022-10-05 | |
| dc.date.issued | 2022 | |
| dc.date.submitted | 2022-09-01 | |
| dc.identifier.citation | 1. Tao, Y.J. and Q. Ye RNA virus replication complexes. PLoS pathogens, 2010. 6, e1000943 DOI: 10.1371/journal.ppat.1000943. 2. Schett, G., M. Sticherling, and M.F. Neurath, COVID-19: risk for cytokine targeting in chronic inflammatory diseases? Nature Reviews Immunology, 2020. 20(5): p. 271-272. 3. Kumar, S., et al., Beyond Vaccines: Clinical Status of Prospective COVID-19 Therapeutics. Front Immunol, 2021. 12: p. 752227. 4. Pascolo, S., Vaccines against COVID-19: Priority to mRNA-Based Formulations. Cells, 2021. 10(10). 5. Tartof, S.Y., et al., Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet, 2021. 398(10309): p. 1407-1416. 6. Hoffmann, M., et al., SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020. 181(2): p. 271-280.e8. 7. Chitalia, V.C. and A.H. Munawar, A painful lesson from the COVID-19 pandemic: the need for broad-spectrum, host-directed antivirals. Journal of Translational Medicine, 2020. 18(1): p. 390. 8. Bai, Z., et al., The SARS-CoV-2 Nucleocapsid Protein and Its Role in Viral Structure, Biological Functions, and a Potential Target for Drug or Vaccine Mitigation. Viruses, 2021. 13(6): p. 1115. 9. Peng, Y., et al., Structures of the SARS-CoV-2 nucleocapsid and their perspectives for drug design. Embo j, 2020. 39(20): p. e105938. 10. Ye, Q., S. Lu, and K.D. Corbett, Structural Basis for SARS-CoV-2 Nucleocapsid Protein Recognition by Single-Domain Antibodies. Frontiers in Immunology, 2021. 12. 11. Z??iga, S., et al., Coronavirus nucleocapsid protein facilitates template switching and is required for efficient transcription. J Virol, 2010. 84(4): p. 2169-75. 12. Cong, Y., et al., Nucleocapsid Protein Recruitment to Replication-Transcription Complexes Plays a Crucial Role in Coronaviral Life Cycle. Journal of Virology, 2020. 94(4): p. e01925-19. 13. Chang, C.K., et al., The SARS coronavirus nucleocapsid protein--forms and functions. Antiviral Res, 2014. 103: p. 39-50. 14. Savastano, A., et al., Nucleocapsid protein of SARS-CoV-2 phase separates into RNA-rich polymerase-containing condensates. Nature Communications, 2020. 11(1): p. 6041. 15. Cubuk, J., et al., The SARS-CoV-2 nucleocapsid protein is dynamic, disordered, and phase separates with RNA. Nature Communications, 2021. 12(1): p. 1936. 16. Zhao, Y., et al., A dual-role of SARS-CoV-2 nucleocapsid protein in regulating innate immune response. Signal Transduction and Targeted Therapy, 2021. 6(1): p. 331. 17. Chen, K., et al., SARS-CoV-2 Nucleocapsid Protein Interacts with RIG-I and Represses RIG-Mediated IFN-β Production. Viruses, 2021. 13(1): p. 47. 18. Pan, P., et al., SARS-CoV-2 N protein promotes NLRP3 inflammasome activation to induce hyperinflammation. Nature Communications, 2021. 12(1): p. 4664. 19. Perrin-Cocon, L., et al., The current landscape of coronavirus-host protein–protein interactions. Journal of Translational Medicine, 2020. 18(1): p. 319. 20. Gordon, D.E., et al., A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature, 2020. 583(7816): p. 459-468. 21. Zhang, X., et al., EF1A interacting with nucleocapsid protein of transmissible gastroenteritis coronavirus and plays a role in virus replication. Vet Microbiol, 2014. 172(3-4): p. 443-8. 22. Zhu, L., et al., The MERS-CoV N Protein Regulates Host Cytokinesis and Protein Translation via Interaction With EF1A. Frontiers in Microbiology, 2021. 12. 23. Zhou, B., et al., The nucleocapsid protein of severe acute respiratory syndrome coronavirus inhibits cell cytokinesis and proliferation by interacting with translation elongation factor 1alpha. J Virol, 2008. 82(14): p. 6962-71. 24. Abbas, W., A. Kumar, and G. Herbein, The eEF1A Proteins: At the Crossroads of Oncogenesis, Apoptosis, and Viral Infections. Frontiers in Oncology, 2015. 5. 25. Mateyak, M.K. and T.G. Kinzy, eEF1A: Thinking Outside the Ribosome *. Journal of Biological Chemistry, 2010. 285(28): p. 21209-21213. 26. Soares, D.C., et al., Structural models of human eEF1A1 and eEF1A2 reveal two distinct surface clusters of sequence variation and potential differences in phosphorylation. PLoS One, 2009. 4(7): p. e6315. 27. Gordon, D.E., et al., Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms. Science, 2020. 370(6521). 28. Ray, M., S. Sarkar, and S.N. Rath, Druggability for COVID-19: in silico discovery of potential drug compounds against nucleocapsid (N) protein of SARS-CoV-2. Genomics Inform, 2020. 18(4): p. e43. 29. Gordon, D.E., et al., A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature, 2020. 583(7816): p. 459-468. 30. Li, D., et al., The unexpected roles of eukaryotic translation elongation factors in RNA virus replication and pathogenesis. Microbiol Mol Biol Rev, 2013. 77(2): p. 253-66. 31. Mills, A. and F. Gago, On the Need to Tell Apart Fraternal Twins eEF1A1 and eEF1A2, and Their Respective Outfits. Int J Mol Sci, 2021. 22(13). 32. Alonso-?lvarez, S., et al., Plitidepsin: design, development, and potential place in therapy. Drug Des Devel Ther, 2017. 11: p. 253-264. 33. Lee, J., et al., Didemnins, tamandarins and related natural products. Natural product reports, 2012. 29: p. 404-24. 34. Losada, A., et al., Translation Elongation Factor eEF1A2 is a Novel Anticancer Target for the Marine Natural Product Plitidepsin. Sci Rep, 2016. 6: p. 35100. 35. S?nchez-Murcia, P.A., ?. Cort?s-Cabrera, and F. Gago, Structural rationale for the cross-resistance of tumor cells bearing the A399V variant of elongation factor eEF1A1 to the structurally unrelated didemnin B, ternatin, nannocystin A and ansatrienin B. J Comput Aided Mol Des, 2017. 31(10): p. 915-928. 36. Papapanou, M., et al., Plitidepsin: Mechanisms and Clinical Profile of a Promising Antiviral Agent against COVID-19. Journal of Personalized Medicine, 2021. 11(7): p. 668. 37. Martinez, M.A., Plitidepsin: a Repurposed Drug for the Treatment of COVID-19. Antimicrobial Agents and Chemotherapy, 2021. 65(4): p. e00200-21. 38. White, K.M., et al., Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A. Science, 2021. 371(6532): p. 926-931. 39. Reuschl, A.-K., et al., Host-directed therapies against early-lineage SARS-CoV-2 retain efficacy against B.1.1.7 variant. bioRxiv, 2021: p. 2021.01.24.427991. 40. Montgomery, D.W. and C.F. Zukoski, Didemnin B: a new immunosuppressive cyclic peptide with potent activity in vitro and in vivo. Transplantation, 1985. 40(1): p. 49-56. 41. MONTGOMERY, D.W., A. CELNIKER, and C.F. ZUKOSKI, DIDEMNIN B–AN IMMUNOSUPPRESSIVE CYCLIC PEPTIDE THAT STIMULATES MURINE HEMAGGLUTINATING ANTIBODY RESPONSES AND INDUCES LEUKOCYTOSIS IN VIVO. Transplantation, 1987. 43(1): p. 133-139. 42. Xu, Y., et al., Bacterial Biosynthesis and Maturation of the Didemnin Anti-cancer Agents. Journal of the American Chemical Society, 2012. 134(20): p. 8625-8632. 43. Varona, J.F., et al., Plitidepsin has a positive therapeutic index in adult patients with COVID-19 requiring hospitalization. medRxiv, 2021: p. 2021.05.25.21257505. 44. Hojyo, S., et al., How COVID-19 induces cytokine storm with high mortality. Inflammation and Regeneration, 2020. 40(1): p. 37. 45. Olbei, M., et al., SARS-CoV-2 Causes a Different Cytokine Response Compared to Other Cytokine Storm-Causing Respiratory Viruses in Severely Ill Patients. Frontiers in Immunology, 2021. 12. 46. Song, P., et al., Cytokine storm induced by SARS-CoV-2. Clinica Chimica Acta, 2020. 509: p. 280-287. 47. Tay, M.Z., et al., The trinity of COVID-19: immunity, inflammation and intervention. Nature Reviews Immunology, 2020. 20(6): p. 363-374. 48. Yang, L., et al., The signal pathways and treatment of cytokine storm in COVID-19. Signal Transduction and Targeted Therapy, 2021. 6(1): p. 255. 49. Bae, H.-G., et al., Detection of yellow fever virus: a comparison of quantitative real-time PCR and plaque assay. Journal of Virological Methods, 2003. 110(2): p. 185-191. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/83518 | - |
| dc.description.abstract | 真核延伸因子1α（eEF1A）是在哺乳類動物細胞中被分為兩種亞型的重要轉譯因子，且先前的藥物篩選研究指出抑制轉譯作用，例如：eEF1A的抑制劑，具有潛在降低新型冠狀病毒（SARS-CoV-2）複製的能力。由於新冠肺炎（COVID-19）的快速肆虐全球，比起發展新療法，舊藥新用能夠緩解人類面臨的緊急情況且更能縮短研發的時間。宿主導向的抗病毒藥物（host-directed antivirals, HDA）因有著低風險的抗藥性而脫穎而出，所以本論文研究的eEF1A的抑制劑Aplidin（Plitidepsin）正符合標準且具有抑制SARS-CoV-2的抗病毒能力。我們研究發現病毒的核殼蛋白（nucleocapsid, N）及細胞eEF1A亞型因子間的交互作用具有在分子病毒學及細胞激素誘發上的研究與治療價值。一開始透過在Calu-3細胞中進行基因表現RNA干擾方法，我們發現eEF1A的兩種亞型，eEF1A1及eEF1A2，都參與了病毒增殖。但有趣的是，我們透過免疫共沉澱的實驗發現N蛋白傾向於與eEF1A1亞型結合，並且更深入確認N蛋白片段（胺基酸第355至363位點，N355-363）是與eEF1A1的重要結合區域（結構域III）。而且，Aplidin在細胞培養中能干預並抑制此結合。此外Aplidin在Vero E6及Calu-3細胞株的病毒感染實驗中證明具有優異地抑制多株代表性SARS-CoV-2變異株的能力。最後，我們也發現到Aplidin能夠有效降低致命性細胞激素表現，例如IL-6。總結來說，我們發現病毒N蛋白會傾向性的與eEF1A1結合，此結合不僅在病毒的複製及生長上扮演重要的角色，並且可能是Aplidin所具有的抗病毒能力及致命性細胞激素的抑制藥用機制。 | zh_TW |
| dc.description.abstract | Eukaryotic elongation factor 1 alpha (eEF1A) is a crucial translation factor with two isoforms that had been identified in mammalian cells for protein synthesis. Previous screening studies have revealed that eEF1A inhibitors have the potential to reduce severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication. Due to the Coronavirus disease 2019 (COVID-19) pandemic has rapidly ravaged the world, in comparison to new regimens and/or drug development, repurposing clinically used drugs can relieve urgency and shorten the period of development time. Notably, host-directed anti-viral drugs (HDA) have stood out with good advantages of low-risk drug resistance and higher safety. Therefore, this dissertation focused on (i) eEF1A inhibitors, specifically Aplidin (Plitidepsin), which meet the above criteria well and also exhibit a surpassing anti-viral activity against SARS-CoV-2; (ii)The interactions between viral nucleocapsid (N) protein and cellular eEF1A isoforms are characterized by molecular virology and cytokine induction; (iii) the mechanism of action of Aplidin, especially in relation with N protein and eEF1A isoform preference. In these above regards, we have found that two eEF1A isoforms, eEF1A1 and eEF1A2, are critically involved in virus reproduction revealed by shRNA knockdown approach using the Calu-3 cell system. Further, co-immunoprecipitation (co-IP) experiments showed that N protein preferentially binds to eEF1A1. Detailed domain-mapping analysis then revealed that the binding motif of N protein located at C-terminus amino acid (a.a.) from 355 to 363 (N355-363) and the N-interacting domain of eEF1A1 was mapped at C-terminus Domain III. The peptide N355-363 was synthesized and, similar to Aplidin, showed an intervention potential in vitro using cellular extracts. Notably, Aplidin showed great antiviral activity against the original strain and prevalent variants of SARS-CoV-2 (such as variant of concern/interest) using both Vero E6 and Calu-3 cellular infection systems. We also found that Aplidin effectively reduced the expression of lethal cytokines, such as IL-6. To sum, we found out a preferential interaction of the eEF1A1 isoform with viral N protein and this interaction not only plays an important role in the viral reproduction but also underlies anti-viral activity and the relieving effect of lethal cytokine expression by Aplidin. | en |
| dc.description.provenance | Made available in DSpace on 2023-03-19T21:09:26Z (GMT). No. of bitstreams: 1 U0001-0109202213394300.pdf: 2696718 bytes, checksum: 1dad55e751633c8dbbda7b934df4d112 (MD5) Previous issue date: 2022 | en |
| dc.description.tableofcontents | 口試委員會審定書 i 致謝 ii 中文摘要 iii ABSTRACT iv CONTENT vi INTRODUCTION 1 1. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 1 2. Eukaryotic Elongation Factor 1 Alpha (eEF1A) 5 3. Aplidin (Plitidepsin) 7 SPECIFIC AIM 9 MATERIALS & METHODS 10 Eukaryotic cell lines and culture medium 10 SARS-CoV-2 infection and viral load quantitation 10 Plaque reduction assay 11 Co-immunoprecipitation (Co-IP), immunoblotting analysis and antibodies 12 Plasmids and Transfection 13 Lentivirus knockdown approach 13 RNA extraction and RT-qPCR assay 14 Peptide 14 Statistics 14 RESULTS 15 1. Both eEF1A1 and eEF1A2 isoforms contributed to viral reproduction 15 2. Interaction between SARS-CoV-2 N protein and eEF1A1 16 3. Aplidin intervention between SARS-CoV-2 N protein and eEF1A1 17 4. Anti-viral activity in Vero E6 and Calu-3 cells of Aplidin 19 5. Aplidin showed different inhibition ability against SARS-CoV-2 variant 20 6. Aplidin showed inhibition ability against cytokines elevated by SARS-CoV-2 infection 21 DISCUSSION 23 Investigate the interaction between cellular eEF1A factor and viral N protein and its intervention 23 Diverse abilities of Aplidin 25 TABLES AND FIGURES 28 Table 1. The vectors, inserts, restriction enzyme digesting sites (D.S.) and primers used in different plasmids 28 Table 2. Table of variant strains with mutation either in Spike (S) or Nucleocapsid (N) proteins 29 Figure 1. Knockdown efficiency and effect on virus infection in Calu-3 cells. 32 Figure 2. Interaction between SARS-CoV-2 N protein and eEF1A1. 33 Figure 3. SARS-CoV-2 N protein and eEF1A1 interaction domain. 36 Figure 4. Aplidin or N peptide intervention between SARS-CoV-2 N protein and eEF1A1 in cell stage or in vitro. 38 Figure 5. Virus inhibition of Aplidin in Vero E6 and Calu-3 cells. 40 Figure 6. Anti-viral ability of Aplidin. 43 Figure 7. Cytokine inhibition rate of 10 nM Aplidin. 45 REFERENCES 46 | |
| dc.language.iso | en | |
| dc.subject | 新型冠狀病毒 | zh_TW |
| dc.subject | 蛋白交互作用 | zh_TW |
| dc.subject | 致命性細胞激素 | zh_TW |
| dc.subject | 宿主導向抗病毒藥物 | zh_TW |
| dc.subject | 真核延伸因子1α | zh_TW |
| dc.subject | 新冠肺炎 | zh_TW |
| dc.subject | 核殼蛋白 | zh_TW |
| dc.subject | lethal cytokines | en |
| dc.subject | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) | en |
| dc.subject | COVID-19 | en |
| dc.subject | Nucleocapsid (N) protein | en |
| dc.subject | Eukaryotic elongation factor 1 alpha (eEF1A) | en |
| dc.subject | Host-directed antivirals (HDA) | en |
| dc.subject | Protein-protein interaction | en |
| dc.title | 探討細胞eEF1A因子與病毒核蛋白間交互作用及干擾 | zh_TW |
| dc.title | Study on functional interactions of cellular eEF1A factor with viral nucleocapsid protein and its intervention | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 110-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 張淑媛(Sui-Yuan Chang),盛望徽(Wang-Huei Sheng) | |
| dc.subject.keyword | 真核延伸因子1α,新型冠狀病毒,新冠肺炎,核殼蛋白,宿主導向抗病毒藥物,蛋白交互作用,致命性細胞激素, | zh_TW |
| dc.subject.keyword | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),COVID-19,Nucleocapsid (N) protein,Eukaryotic elongation factor 1 alpha (eEF1A),Host-directed antivirals (HDA),Protein-protein interaction,lethal cytokines, | en |
| dc.relation.page | 49 | |
| dc.identifier.doi | 10.6342/NTU202203056 | |
| dc.rights.note | 未授權 | |
| dc.date.accepted | 2022-09-02 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 微生物學研究所 | zh_TW |
| 顯示於系所單位： | 微生物學科所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| U0001-0109202213394300.pdf 未授權公開取用 | 2.63 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。